Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01853163 · ClinicalTrials.gov registry record · NA
Long-Term Retention of Gadolinium in Bone
A NA study of Focus: Long-term Retention of Gadolinium-based Contrast Agent, sponsored by Navitas Life Sciences.
- Completed
- Registry status
- NA
- Development phase
- 92
- Enrollment target
- 16
- Study locations
NCT01853163: Completed NA study of Focus: Long-term Retention of Gadolinium-based Contrast Agent, sponsored by Navitas Life Sciences.
NCT01853163 is a NA study of Focus: Long-term Retention of Gadolinium-based Contrast Agent that has completed, run by Navitas Life Sciences. The registered enrollment target is 92 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). The trial reports 16 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01853163, a NA study of Focus: Long-term Retention of Gadolinium-based Contrast Agent, has completed, sponsored by Navitas Life Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 92 participants
- Enrollment target
- 16
- Study locations
Study Summary
The main objective was to prospectively explore the potential for long-term retention of Gadolinium (Gd) in bones in patients who have received a single dose of Gadolinium-based contrast agents (GBCA) or multiple doses of the same GBCA, with moderate or severe renal impairment or stable normal renal function (eGFR \> 60 ml/min/1.73 m2) at the time of GBCA injection.
Primary Outcome
Concentration of total Gd in trabecular bone determined by ICP-MS
Conditions Studied
Interventions
- PROCEDURE Gadolinium analysis in bone and tissue samples
Study Locations (16)
Other
- University Hospital Halle (Saale) - Halle
- University Hospital Magdeburg - Magdeburg
- University Hospital Würzburg - Würzburg
- Fukuoka Orthopaedic Hospital - Fukuoka
- Nissan Tamagawa Hospital - Tokyo
- Asan Medical Center Orthopedic Surgery - Seoul
- SMG-SNU Boramae Medical Center - Seoul
- Hospital Universitario Fundación Alcorcón - Alcorcón
- Hospital Vall d'Hebron - Barcelona
- H.G.U. Gregorio Marañón - Madrid
- Koc University Hospital, Orthopaedics and Traumatology Department - Istanbul
- Acibadem Hospital, Department of Orthopaedics and Traumatology - Istanbul
- Fatih Sultan Mehmet Training and Research Hospital, Department of Orthopedics and Traumatology - Istanbul
- Istanbul Sisli Hamidiye Etfal Egitim ve Arastirma Hastanesi - Istanbul
- Dokuz Eylul University Tıp Faculty - Izmir
California
- Cedar-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-05-06 |
| Est. Completion | 2018-12-17 |
| Phase | NA |
What the finished NCT01853163 record still lists
NCT01853163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 92 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Focus: Long-term Retention of Gadolinium-based Contrast Agent appearing as the primary indexed condition, and to 1 intervention - of which Gadolinium analysis in bone and tissue samples is the first listed.
NCT01853163 lists 16 locations in 2 states (Other, California).
Frequently Asked Questions
What is clinical trial NCT01853163 about?
NCT01853163 is a clinical study titled "Long-Term Retention of Gadolinium in Bone". The main objective was to prospectively explore the potential for long-term retention of Gadolinium (Gd) in bones in patients who have received a single dose of Gadolinium-based contrast agents (GBCA) or multiple doses of the same GBCA, with moderate or severe renal impairment or stable normal renal...
What is the current status of trial NCT01853163?
This trial is currently completed. It is a NA study. The enrollment target is 92 participants. The study started on 2013-05-06. Estimated completion is 2018-12-17.
What conditions does trial NCT01853163 study?
This clinical trial studies the following conditions: Focus: Long-term Retention of Gadolinium-based Contrast Agent.
What interventions are being tested in trial NCT01853163?
The interventions under investigation include: Gadolinium analysis in bone and tissue samples (PROCEDURE).
Who is sponsoring clinical trial NCT01853163?
This trial is sponsored by Navitas Life Sciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01853163 being conducted?
This trial has 16 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01853163's enrollment target sits among peer trials
92 937th of 2000 higher than 1,062 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03184545 · 92 participants · Phase 3
Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome
- NCT04172532 · 92 participants · Phase 1
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
- NCT04508088 · 92 participants
Skeletal Health and Bone Marrow Composition in Newly Diagnosed Adolescents With Crohn Disease
- NCT04840602 · 92 participants · Phase 2
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI